絞り込み

16645

広告

「"Grauer A"[Author]」の検索結果

114件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures.

Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study.

Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States.

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.

Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials.

Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.

Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials.

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.

Risk of subsequent fracture after prior fracture among older women.

Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome.

Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study.

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.

Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression.

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.

Predictors of near-term fracture in osteoporotic women aged ≥65 years, based on data from the study of osteoporotic fractures.

Greater Gains in Spine and Hip Strength for Romosozumab Compared to Teriparatide in Postmenopausal Women With Low Bone Mass.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
Sort by
※並べ替えは表示に時間がかかります